HS-10296 |
| Catalog No.GC39560 |
HS-10296 (HS-10296) est un inhibiteur de tyrosine kinase EGFR de troisième génération, disponible par voie orale, irréversible, avec une sélectivité élevée pour les mutations de sensibilisation À l'EGFR et de résistance T790M. HS-10296 montre une grande activité inhibitrice contre T790M, T790M/L858R et T790M/Del19 (IC50 : 0,37, 0,29 et 0,21 nM, respectivement), et est moins efficace contre le type sauvage (3,39 nM). HS-10296 est utilisé pour la recherche sur le cancer du poumon non À petites cellules.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1899921-05-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HS-10296, an orally available and third-generation EGFR-activating mutations and T790M-resistant mutation inhibitor, shows limited activity against wild-type EGFR[1][2].
[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. [2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *